MNCM News

"The two words ‘information’ and ‘communication’ are often used interchangeably, but they signify quite different things. Information is giving out; communication is getting through." -- Sydney J. Harris

MNCM Seeking Medical Group Testing Participants for COPD Measure Development

Indicate Interest by 02/28/2018

MN Community Measurement (MNCM) is seeking volunteers to participate in the pilot testing of a new measure for chronic obstructive pulmonary disease—Controlling the Impact of COPD on Health Status. Pilot testing focuses on the development and testing of a patient reported outcome (PRO) performance measure.

The measure was developed by a MNCM-convened, multi-stakeholder COPD Measure Development Workgroup, which completed the development of measure specifications in November 2016.

Measure Description:

The percentage of patients aged 50 – 80 years whose self-reported impact of COPD on their health status was low, stable or improved, as determined by the COPD Assessment Test (CAT) or Clinical COPD Questionnaire (CCQ). For more details, view Controlling the Impact of COPD on Health Status Measure and Field Specifications.

Family medicine, internal medicine, geriatric medicine and pulmonology practices that care for patients with COPD are encouraged to participate in the pilot. There are many benefits to participating in a pilot project, including but not limited to: implementation of PRO tools into clinical workflows and electronic record systems, providing feedback for the modification of measure specifications, the ability to have baseline data prior to wide-spread implementation, and the opportunity to gain experience in the measurement activity. Eligible medical groups will be compensated for the pilot– up to $2,000 after execution of contract, and up to $8,000 after successful data submission.

In order to have a representative and informative pilot, we need groups to volunteer to participate! Pilot dates of service start April 1, 2018.

Participation is voluntary, and all results used to analyze the measure’s performance and feasibility will be shared with pilot participants, blinded and not publicly reported.

If you are interested in potentially serving as a test site, please complete this brief survey.  We will review the survey responses to help us select eligible practices.

If you have questions, please contact Tony Weldon at weldon@mncm.org or 612-454-4810. We look forward to working with you!

About this Project

MNCM is leading this measure development project with support from the National Quality Forum (NQF) Measure Incubator™. GlaxoSmithKline, a global leader in respiratory disease, is collaborating with the Measure Incubator as the sponsor of the project. See the NQF website to learn more about the Measure Incubator’s current work.